Spruce Biosciences (SPRB) Share-based Compensation (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Share-based Compensation of $10000.0 for Q1 2026, down 98.16% year-over-year from $544000.0 in Q1 2025, and up 119.61% quarter-over-quarter from -$51000.0 in Q4 2025.
Spruce Biosciences (SPRB) Share-based Compensation (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Share-based Compensation for 8 consecutive years, with $10000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 98.16% year-over-year to $10000.0; the TTM figure through Mar 2026 stood at $297000.0 (down 93.14% YoY), while the FY2025 annual figure was $3.5 million, down 34.55% from the prior year.
- Share-based Compensation climbed to $10000.0 in Q1 2026 per SPRB's latest filing, from -$51000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.6 million in Q4 2022 and bottomed at -$3.4 million in Q4 2023.
- Historically, Share-based Compensation has averaged $652625.0 across 5 years, with a median of $844000.0 in 2022.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 194.4% — and 2024, when it jumped 6691.3%.
- Spruce Biosciences' Share-based Compensation stood at $3.6 million in 2022, then tumbled by 194.4% to -$3.4 million in 2023, then surged by 128.35% to $961000.0 in 2024, then slumped by 105.31% to -$51000.0 in 2025, then surged by 119.61% to $10000.0 in 2026.
- Business Quant data shows SPRB's Share-based Compensation at $10000.0 in Q1 2026, -$51000.0 in Q4 2025, and $415000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Spruce Biosciences | 123.45 Mn | 123.45 Mn | - | 871,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 871,000.00 |
| Jun 30, 2026 | 871,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Sep 30, 2025 | 415,000.00 |
| Sep 30, 2025 | 415,000.00 |
| Jun 30, 2025 | -77,000.00 |
| Jun 30, 2025 | -77,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Dec 31, 2024 | 961,000.00 |
| Dec 31, 2024 | 961,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 1.69 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Mar 31, 2024 | 1.56 Mn |